BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36443849)

  • 1. Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy.
    Oertel M; Borrmann K; Baehr A; Eich HT; Greve B
    Radiat Oncol; 2022 Nov; 17(1):194. PubMed ID: 36443849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
    Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
    Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
    Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
    Ugurel S; Schadendorf D; Horny K; Sucker A; Schramm S; Utikal J; Pföhler C; Herbst R; Schilling B; Blank C; Becker JC; Paschen A; Zimmer L; Livingstone E; Horn PA; Rebmann V
    Ann Oncol; 2020 Jan; 31(1):144-152. PubMed ID: 31912789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
    Stevenson VB; Perry SN; Todd M; Huckle WR; LeRoith T
    Vet Pathol; 2021 Jul; 58(4):692-698. PubMed ID: 34169800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
    Ren Y; Lv Q; Yue W; Liu B; Zou Z
    Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.
    Wei H; Wu F; Mao Y; Zhang Y; Leng G; Wang J; Zhang W; Wang T
    Jpn J Clin Oncol; 2022 Apr; 52(4):331-345. PubMed ID: 35106596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.
    Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
    BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
    Sanmamed MF; Perez-Gracia JL; Schalper KA; Fusco JP; Gonzalez A; Rodriguez-Ruiz ME; Oñate C; Perez G; Alfaro C; Martín-Algarra S; Andueza MP; Gurpide A; Morgado M; Wang J; Bacchiocchi A; Halaban R; Kluger H; Chen L; Sznol M; Melero I
    Ann Oncol; 2017 Aug; 28(8):1988-1995. PubMed ID: 28595336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
    Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity.
    Hirahara S; Katsumata Y; Kawasumi H; Kawaguchi Y; Harigai M
    Lupus; 2020 Jun; 29(7):686-696. PubMed ID: 32264742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
    Koelzer VH; Gisler A; Hanhart JC; Griss J; Wagner SN; Willi N; Cathomas G; Sachs M; Kempf W; Thommen DS; Mertz KD
    Histopathology; 2018 Sep; 73(3):397-406. PubMed ID: 29660160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
    Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H
    Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.